- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07724405
Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage (GEM)
A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer
Recurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both distressing and disorienting for affected families, particularly in settings such as the United Arab Emirates (UAE), where childbearing carries significant personal and cultural weight.
One leading hypothesis is that the underlying problem may not lie with the embryo itself, but with the way the mother's immune system responds to a developing pregnancy. Under normal physiological conditions, the maternal body must establish immune tolerance toward an embryo that is genetically half-foreign in origin. In some women, this tolerance mechanism may be impaired, reducing the likelihood that a pregnancy will successfully implant and progress.
This study will evaluate whether granulocyte colony-stimulating factor (G-CSF) a naturally occurring substance that normally stimulates the production of immune cells can help address this issue by modulating an overactive immune response and enhancing the uterine environment's capacity to support pregnancy. Notably, the study will enroll only women whose embryos have undergone genetic testing and been confirmed to be chromosomally normal. This eliminates embryo quality as a contributing factor to pregnancy loss and allows for a clearer assessment of whether G-CSF itself influences outcomes.
Earlier small-scale studies, including preliminary work conducted at our own centre, have shown encouraging results. This new trial builds on that foundation by enrolling a larger cohort, comparing G-CSF against a placebo (an inactive comparison treatment), and evaluating a simpler route of administration; subcutaneous injection, rather than direct infusion into the uterus. Together, these design features aim to provide the most reliable evidence to date on whether this treatment can meaningfully help couples affected by unexplained recurrent pregnancy loss.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Recurrent pregnancy loss (RPL) defined as two or more consecutive miscarriages before 20 weeks' gestation affects 1-2% of couples worldwide and remains one of the most distressing, poorly resolved conditions in reproductive medicine. In nearly half of cases, no definitive cause is identified. This burden is especially pronounced in the UAE and wider GCC region, where delayed childbearing and the strong sociocultural weight placed on fertility amplify the psychological, marital, and financial toll of unexplained RPL.
Despite decades of research, treatment remains largely empirical. Immune dysregulation is increasingly implicated as a central mechanism, with proposed pathways including aberrant natural killer (NK) cell activation, impaired regulatory T-cell expansion, inadequate decidualization, and an unfavorable Th1/Th17 cytokine profile, collectively compromising endometrial receptivity and embryo survival. However, most supporting studies have been small, uncontrolled, and unable to distinguish maternal immunological causes from embryo genetic abnormalities, leaving clinicians with few evidence-based options.
Granulocyte colony-stimulating factor (G-CSF), a hematopoietic cytokine with immunomodulatory and endometrial effects, has emerged as a promising candidate. Preclinical and early clinical data suggest it enhances endometrial proliferation and vascularization, supports folliculogenesis and oocyte competence, and promotes immune tolerance by expanding regulatory T-cells while reducing NK cell cytotoxicity. Small trials in both recurrent implantation failure and RPL populations have reported benefits in implantation and live birth rates, though results have been inconsistent - largely due to the same methodological limitations noted above, plus a failure to control for embryo aneuploidy as a confounder.
Our own retrospective pilot study of 19 patients receiving intrauterine G-CSF supports this rationale: 70.5% achieved a positive β-hCG, 66.7% progressed to ongoing pregnancy, and no adverse effects were observed. These findings demonstrate both feasibility and preliminary efficacy at our centre. However, intrauterine infusion is invasive, costly, and less patient-friendly; existing literature suggests subcutaneous administration may achieve comparable efficacy with greater convenience, but this route has not yet been evaluated in this specific population.
The GEM Trial is designed to resolve these open questions directly. By enrolling women with unexplained RPL undergoing IVF with preimplantation genetic testing for aneuploidy (PGT-A), the trial eliminates embryo chromosomal abnormality as a confounder, enabling a precise, mechanistically targeted test of the immunological hypothesis. It will be the first placebo-controlled, genetically controlled trial of G-CSF in this population, and the first to formally assess subcutaneous delivery.
If successful, the GEM Trial could establish a new standard of care for unexplained RPL offering a more convenient, evidence-based treatment option to thousands of couples and positioning the UAE as a global leader in reproductive immunology research.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Dr. Lamiya Mohiyiddeen, MD, FRCOG
- Telefonszám: +971543676002
- E-mail: lamiya.mohiyiddeen@fakihivf.com
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Fatma Bathawab, PhD
- Telefonszám: +971585707393
- E-mail: fatma.bathawab@fakihivf.com
Tanulmányi helyek
-
-
-
Abu Dhabi, Egyesült Arab Emírségek
- Toborzás
- Fakih IVF Fertility Centre LLC
-
Kapcsolatba lépni:
- Dr. Lamiya Mohiyiddeen, MD, FRCOG
- Telefonszám: +971543676002
- E-mail: lamiya.mohiyiddeen@fakihivf.com
-
Kapcsolatba lépni:
- Fatma Bathawab, PhD
- Telefonszám: +971585707393
- E-mail: fatma.bathawab@fakihivf.com
-
Kutatásvezető:
- Michael Fakih, MD
-
Kutatásvezető:
- Lamiya Mohiyiddeen, MD, FRCOG
-
Kutatásvezető:
- Yasmin Sajjad, MD, FRCOG
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion:
- Women aged 18-44 years
- ≥2 unexplained pregnancy losses
- Undergoing IVF with PGT-A tested embryos
- BMI 19-35 kg/m² 6.
Exclusion:
- Parental karyotype abnormalities
- Correctable uterine abnormalities
- Systemic autoimmune disease / thrombophilia
- Uncontrolled systemic illness (e.g. diabetes, infection)
- Previous G-CSF therapy
- Hypersensitivity to rhG-CSF or E. coli proteins
- HIV, malignancy within 5 years, or severe cardiovascular/respiratory history
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Négyszeres
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Recombinant G-CSF 130 mcg SC
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
|
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
|
|
Placebo Comparator: Placebo Control: Placebo SC
Subcutaneous injection of placebo daily from embryo transfer until 12 weeks' gestation
|
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Clinical pregnancy rate
Időkeret: From enrollment to 16 weeks gestation
|
Clinical pregnancy confirmation by transvaginal ultrasound at 16 weeks' gestation.
|
From enrollment to 16 weeks gestation
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Live birth rate
Időkeret: From enrollment to approximately 40 weeks' gestation.
|
From enrollment to approximately 40 weeks' gestation.
|
|
|
Ongoing Pregnancy Rate
Időkeret: From 16 weeks to 34 weeks gestation.
|
16 - 34 weeks gestation by serial ultrasound.
|
From 16 weeks to 34 weeks gestation.
|
|
Early Pregnancy Loss rate
Időkeret: From FET (Fetal Embryo Transfer) to 12 weeks gestation
|
Pregnancy loss confirmed by a transvaginal ultrasound.
|
From FET (Fetal Embryo Transfer) to 12 weeks gestation
|
|
Rate of Adverse pregnancy outcomes (APOs)
Időkeret: From enrollment to approximately 40 weeks gestation
|
Rate of Miscarriage, stillbirth, neonatal outcomes (birth weight, NICU admission, congenital anomalies) and maternal outcomes assessed using several methods including transvaginal ultrasound and clinical assessment.
|
From enrollment to approximately 40 weeks gestation
|
|
Rate of Adverse events
Időkeret: From enrollment up to approximately 40 weeks gestation (delivery)
|
Safety data including pregnancy related, fetal or maternal adverse events e.g.
infections, cytopenias, hypersensitivity etc.
|
From enrollment up to approximately 40 weeks gestation (delivery)
|
|
Rate of immunogenicity
Időkeret: From enrollment to up to approximately 40 weeks gestation (delivery)
|
Anti-drug antibody (ADA) formation (serology in subset).
|
From enrollment to up to approximately 40 weeks gestation (delivery)
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Általános kiadványok
- Scarpellini F, Sbracia M. Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum Reprod. 2009 Nov;24(11):2703-8. doi: 10.1093/humrep/dep240. Epub 2009 Jul 17.
- Barad DH, Yu Y, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ, Gleicher N. A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates. Fertil Steril. 2014 Mar;101(3):710-5. doi: 10.1016/j.fertnstert.2013.12.016. Epub 2014 Jan 11.
- ESHRE Guideline Group on RPL; Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, Middeldorp S, Mcheik S, Peramo B, Quenby S, Nielsen HS, van der Hoorn ML, Vermeulen N, Goddijn M. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023 Mar 2;2023(1):hoad002. doi: 10.1093/hropen/hoad002. eCollection 2023.
- Impact of Intrauterine Infusion vs Subcutaneous G-CSF Injection on Endometrial Immunomodulation and Angiogenesis in Infertile Women undergoing IUI; Zainab AbdulQaderMahmood, LubnaAmerAl-Anbari, ManalTahaAl-Obaidi, 2025 Trends in Immunotherapy|Volume 09|Issue 03
- P-347 A comparative RCT of Intrauterine-GCSF versus Subcutaneous-GCSF in Thin Endometrium in IVF-ICSI Cycles, P C Jindal, M Singh, Human Reproduction, Volume 36, Issue Supplement_1, July 2021, deab130.346
- GCSF in patients with thin endometrium-subcutaneous or intrauterine?, Shilpa Singal, R.K. Sharma, Nupur Ahuja, Fertility Science and research 10.4103/2394-4285.288714
- Eftekhar M, Miraj S, Najafian A. Efficacy of intrauterine infusion of G-CSF in infertile women: a systematic review and meta-analysis. Int J Reprod Biomed. 2016;14(9):557-566.
- Santjohanser C, Hosseini M, Schönleber J, et al. G-CSF in patients with recurrent miscarriage and recurrent implantation failure: a prospective, randomized, double-blind, placebo-controlled trial. Hum Reprod. 2013;28(1):72-79.
- Wurfel W. Treatment with granulocyte colony-stimulating factor in patients with repetitive implantation failures and/or recurrent spontaneous abortions. J Reprod Immunol. 2015 Apr;108:123-35. doi: 10.1016/j.jri.2015.01.010. Epub 2015 Feb 21.
- Kwak-Kim J, Bao S, Lee SK, Kim JW, Gilman-Sachs A. Immunological modes of pregnancy loss: inflammation, immune effectors, and stress. Am J Reprod Immunol. 2014 Aug;72(2):129-40. doi: 10.1111/aji.12234. Epub 2014 Mar 24.
- Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010 Jun;63(6):601-10. doi: 10.1111/j.1600-0897.2010.00852.x. Epub 2010 Apr 23.
- American Society for Reproductive Medicine (ASRM). Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2023;120(6):1255-1271.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- FAKIH-2025-10
- DOH/ADHRTC/2026/34566666666666 (Egyéb azonosító: Department of Health Abu Dhabi)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .